Business
electroCore Announces Reimbursement Approval for gammaCore™ by RIZIV/INAMI in Belgium
ROCKAWAY, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that gammaCore™ Sapphire (nVNS) has been included in a long-term reimbursement policy launched by the National Institute for Health and Disability Insurance (RIZIV / INAMI) in Belgium. Effective October 1, 2025, the policy provides coverage for gammaCore Sapphire to treat patients with cluster headaches. This coverage is based on str
About this update from Electrocore, Inc.
ROCKAWAY, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that gammaCore™ Sapphire (nVNS) has been included in a long-term reimbursement policy launched by the National Institute for Health and Disability Insurance (RIZIV / INAMI) in Belgium. Effective October 1, 2025, the policy provides coverage for gammaCore Sapphire to treat patients with cluster headaches. This coverage is based on strong clinical evidence supporting the therapy’s efficacy and cost-effectiveness and ensures broader access for Belgian patients. “The reimbursement of gammaCore by RIZIV / INAMI is a remarkable step forward for patients suffering from cluster headaches in Belgium,” said Prof. Paemeleire, leading the Headache Clinic of the Neurology Department at Ghent University Hospital. “This decision reflects the growing recognition of the clinical and economic benefits of non-invasive vagus nerve stimulation. As a healthcare provider, I am pleased that this reimbursement will now allow more patients to access a therapy that can significantly improve their daily lives while contributing to a more sustainable healthcare system.” This achievement was made possible through the leadership and commitment of Silvert Medical, electroCore’s distribution partner in Belgium. Silvert Medical leveraged their local expertise and strong provider relationships, playing a key role in securing reimbursement. Silvert Medical remains a vital partner in supporting the rollout of gammaCore in Belgium and is committed to extending access to gammaCore in neighboring countries. “Securing long-term reimbursement in Belgium, in the center of Europe, is a major milestone in expanding access to our non-invasive therapies,” said Tanja Martin, Senior Director of Strategic Product Lifecycle at electroCore. “We’re proud to partner with Silvert Medical to bring gammaCore to patients in Belgium.” Learn more about RIZIV / INAMI’s reimbursement policy for gammaCore Sapphire here. About electroCore, Inc. electroCore, Inc. is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator,...